The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage

Torensma, Ruurd

doi:10.3390/cancers10110431

Cited by 9 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, there is still an ongoing debate to which extent WHO grade II tumors should be treated, especially in young patients. In this case, the maintenance of quality of life should be one of the highest priorities and needs to be weighed against the risks and benefits of treatment [12]. Here we report a relatively small cohort of 44 molecular defined oligodendroglioma, reflecting the rarity of this tumor entity.…”

Section: Discussionmentioning

confidence: 84%

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

et al. 2020

View full text Add to dashboard Cite

Background: Oligodendroglioma (ODG) are CNS resistant tumors characterized by their unique molecular signature, namely a combined deletion of 1p and 19q simultaneously to an IDH1/2 mutation. These tumors have a more favorable clinical outcome compared to other gliomas and a long-time survival that ranges between 10 and 20 years. However, during the course of the disease, multiple recurrences occur and the optimal treatment at each stage of the disease remains unclear. Here we report a retrospective longitudinal observation study of 836 MRI examinations in 44 ODG patients. Methods: We quantified the volume of T2-hyperintensity to compute growth behavior in dependence of different treatment modalities, using various computational models. Results: The identified growth pattern revealed dynamic changes, which were found to be patient-specific an did not correlate with clinical parameter or therapeutic interventions. Further, we showed that, surgical resection is beneficial for overall survival regardless the WHO grad or timepoint of surgery. To improve overall survival, an extent of resection above 50% is required. Multiple resections do not generally improve overall survival, except a greater extent of resection than in previous surgeries was achieved. Conclusions: Our data aids to improve the interpretation of MRI images in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 84%

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, there is still an ongoing debate to which extent WHO grade II tumors should be treated, especially in young patients. In this case, the maintenance of quality of life should be one of the highest priorities and needs to be weighed against the risks and benefits of treatment [10]. Here we report a relatively small cohort of 44 molecular defined oligodendroglioma, reflecting the rarity of this tumor entity.…”

Section: Discussionmentioning

confidence: 92%

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

Heiland

Ohle

Cipriani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Oligodendroglioma (ODG) are CNS resistant tumors characterized by their unique molecular signature, namely a combined deletion of 1p and 19q simultaneously to an IDH1/2 mutation. These tumors have a more favorable clinical outcome compared to other gliomas and a long-time survival that ranges between 10-20 years. However, during the course of the disease, multiple recurrences occur and the optimal treatment at each stage of the disease remains unclear. Here we report a retrospective longitudinal observation study of 836 MRI examinations in 44 ODG patients. Methods: We quantified the volume of T2-hyperintensity to compute growth behavior in dependence of different treatment modalities, using various computational models. Results: The identified growth pattern revealed dynamic changes, which were found to be patient-specific an did not correlate with clinical parameter or therapeutic interventions. Further, we showed that, surgical resection is beneficial for overall survival regardless the WHO grad or timepoint of surgery. To improve overall survival, an extent of resection above 50% is required. Multiple resections do not generally improve overall survival, except a greater extent of resection than in previous surgeries was achieved. Conclusions: Our data aids to improve the interpretation of MRI images in clinical practice.

show abstract

“…Though HGG therapy gives the patients an extended overall survival, it comes with an actual impedance [ 94 ]. For example, in oligodendroglioma, ~4% of the cancer stem cells (CSC) are cycling stem cells that promote tumor growth and recurrence.…”

Section: Challenges In Hgg Standard Therapymentioning

confidence: 99%

“…For example, in oligodendroglioma, ~4% of the cancer stem cells (CSC) are cycling stem cells that promote tumor growth and recurrence. In comparison, the remaining 96% are non-cycling cancer cells that are resistant to chemotherapy and radiotherapy [ 94 , 95 , 96 ]. Mutation of IDH renders cells incapable of fully utilizing the citric acid cycle, which creates ATP deprivation, leading to a low cell cycle performance [ 94 ].…”

Section: Challenges In Hgg Standard Therapymentioning

confidence: 99%

“…In comparison, the remaining 96% are non-cycling cancer cells that are resistant to chemotherapy and radiotherapy [ 94 , 95 , 96 ]. Mutation of IDH renders cells incapable of fully utilizing the citric acid cycle, which creates ATP deprivation, leading to a low cell cycle performance [ 94 ]. Although chemo-radiotherapy has substantial benefits in prolonging the median overall survival (>14 years), even after the prescription has been repealed by six rounds and the dose has been lowered, the mortality rate remains high.…”

Section: Challenges In Hgg Standard Therapymentioning

confidence: 99%

See 1 more Smart Citation

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

et al. 2021

View full text Add to dashboard Cite

Despite their low incidence rate globally, high-grade gliomas (HGG) remain a fatal primary brain tumor. The recommended therapy often is incapable of resecting the tumor entirely and exclusively targeting the tumor leads to tumor recurrence and dismal prognosis. Additionally, many HGG patients are not well suited for standard therapy and instead, subjected to a palliative approach. HGG tumors are highly infiltrative and the complex tumor microenvironment as well as high tumor heterogeneity often poses the main challenges towards the standard treatment. Therefore, a one-fit-approach may not be suitable for HGG management. Thus, a multimodal approach of standard therapy with immunotherapy, nanomedicine, repurposing of older drugs, use of phytochemicals, and precision medicine may be more advantageous than a single treatment model. This multimodal approach considers the environmental and genetic factors which could affect the patient’s response to therapy, thus improving their outcome. This review discusses the current views and advances in potential HGG therapeutic approaches and, aims to bridge the existing knowledge gap that will assist in overcoming challenges in HGG.

show abstract

The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage

Cited by 9 publications

References 46 publications

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

Contact Info

Product

Resources

About